janssen_latest_logo_on_sign_closer

European Commission expands Stelara for paediatric moderate to severe plaque psoriasis

pharmafile | January 24, 2020 | News story | Research and Development Europe, Janssen, Stelara, pharma 

Janssen’s Stelara (ustekinumab) has seen its label expanded in Europe to include the treatment of moderate to severe plaque psoriasis in children aged from 6 to 11, it has emerged.

The approval followed a previous positive opinion from the EMA’s Committee for Medicinal Products for Human Use marks the availability in Europe of the first biologic within this patient group to target the IL-23/IL-12 pathway

Phase 3 data submitted in support of the decision showed that the therapy met its primary endpoint of the proportion of patients who achieved a physician’s global assessment (PGA) score of either cleared (0) or minimal (1) after 12 weeks of treatment. The drug also showed benefit in improving quality of life as well as the signs and symptoms of plaque psoriasis.

“This latest EC approval is a significant milestone for young children struggling to cope with the symptoms of psoriasis,” said Lloyd Miller, Vice President, Immunodermatology Disease Area Leader at Janssen. “We’re delighted that this therapy, which has a well-established safety and efficacy profile in adults with plaque psoriasis and other immune diseases, is now expanded to children as young as six who are living with this chronic disease.”

Advertisement

Around a third of the 14 million incidence of psoriasis in Europe affect children, and the condition can impact mental health and quality of life in the long term.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content